穿孔素1(PRF1)重組蛋白
Recombinant Perforin 1 (PRF1)
FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein
- 編號RPB317Ra01
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜, 分泌, 內(nèi)質(zhì)網(wǎng)腔
- 預(yù)測分子量29.6kDa
- 實際分子量33kDa(差異分析請參閱說明書)
- 片段與標簽Ala120~Asp353 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點6.4
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1128 ¥ 2820 ¥ 5640 ¥ 16920 ¥ 42300
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列

用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB317Ra01 | 穿孔素1(PRF1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB317Ra01 | 穿孔素1(PRF1)活性蛋白 | Cell?culture;?Activity?Assays. |
PAB317Ra01 | 穿孔素1(PRF1)多克隆抗體 | WB; IHC; ICC; IP. |
MAB317Ra21 | 穿孔素1(PRF1)單克隆抗體 | WB; IHC; ICC; IP. |
SEB317Ra | 穿孔素1(PRF1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB317Ra | 穿孔素1(PRF1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Diagnostic Microbiology and Infectious Disease | Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection [Pubmed:26915636] |
FASEB?JOURNAL | The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis [Pubmed: 30951375] |
Theranostics | A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors [Pubmed: 31695790] |
Mol Immunol | CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection [Pubmed: 33223223] |
INVESTIGATIONAL NEW DRUGS | Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors [Pubmed: 32772342] |
Am J Transl Res | Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma [34377237] |
Nat Biomed Eng | Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy [34873307] |
J Exp Med | Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion [Pubmed:35061012] |
留言咨詢